TrialGynecologic oncology2008

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Halla S Nimeiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.